Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.

[1] It binds to IL17A and acts as an immunomodulator.

[2] This drug was developed by Genentech/Roche.

Immune activation: Dostarlimab Other: Ibalizumab

This monoclonal antibody–related article is a stub.